Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Psoriasis Clinical Trial

Official title:

A Double-Blind, Randomized Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00759161
• Other study ID #: AN2728-PSR-201
• Status: Completed
• Phase: Phase 2
• First received: September 23, 2008
• Last updated: February 9, 2011
• Start date: November 2007
• Est. completion date: March 2008

Study information

• Verified date: February 2011
• Source: Anacor Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationMexico: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle in the treatment of plaque type psoriasis.

Description:

This is a multi-center, randomized, double-blind bilateral design. Patients will apply the test articles, AN2728 Ointment, 5%, and Ointment Vehicle twice daily. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test article will be applied to one plaque and the other test article to an anatomically distinct plaque. All efficacy evaluations will be measured from only the two plaques identified at the baseline visit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female >18 years of age at time of enrollment.

2. The clinical diagnosis of stable plaque psoriasis.

3. Two target plaques of similar severity

1. = 5 cm2 but = 100 cm2 computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter.

2. Bilaterally located (right/left) plaques on the arms or plaques located on the upper and lower trunk. Plaques located on the trunk were to be separated by at least 10 cm and designated by the Investigator as either left/right or front/back.

3. Target plaque severity score of 2-4 (mild to moderate).

4. Normal or not clinically significant screening laboratory results.

5. Subjects who were willing and able to apply study drug as directed, comply with study instructions, and commit to all follow-up visits.

6. Subjects who had the ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures.

Exclusion Criteria:

1. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation

2. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below)

3. Known sensitivity to any of the components of the study medication

4. Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis

5. Concomitant use of topical or systemic therapies that might alter the course of psoriasis

6. Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (oophorectomy)

7. Washout periods of:

1. Topical drugs that might alter the course of psoriasis: 2 weeks

2. Oral retinoids: 8 weeks

3. Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks

4. PUVA: 4 weeks

5. UVB therapy: 4 weeks

6. Use of emollients/moisturizers on area(s) to be treated: 2 days prior to baseline visit

8. AIDS or AIDS related illness

9. Concurrent participation in another drug research study or within 30 days of enrollment

10. Use of lithium or hydroxychloroquine containing products (i.e. Plaquenil)

11. Use of a beta-blocking medication (i.e. propranolol) if the dose has not been stabilized for at least 3 months

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• AN2728
AN2728 Ointment, 5%, twice daily for 4 weeks
• AN2728 Ointment Vehicle
AN2728 Ointment Vehicle, twice daily for 4 weeks.

Locations

Country	Name	City	State
Mexico	IMIC	Mexico City	Distrito Federal

Sponsors (1)

Lead Sponsor	Collaborator
Anacor Pharmaceuticals, Inc.

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Target Plaque Severity Assessment (OTPSS) at Day 28		Day 28	No
Secondary	Change of Overall Target Plaque Severity Score and erythema, scaling and plaque elevation assessments from baseline		Days 7, 14, 21, 28 and 35	No
Secondary	Overall Target Plaque Severity Assessment (OTPSS) at Days 7, 14, 21 and 35		Days 7, 14, 21 and 35	No